Meeting Banner
Abstract #2152

Chronic methylene blue treatment decreases ischemic stroke volume and improves functional behavioral recovery

Pavel Rodriguez 1 , Jiang (John) Zhao 1,2 , and Timothy Q. Duong 1

1 Research Imaging Institute, The University of Texas Health Science Center, San Antonio, Texas, United States, 2 Department of Anatomy and Embryology, Peking University Health Science Center, Beijing, United States

We previously reported that a single-dose methylene blue (MB), an energy-enhancing drug, given hyperacutely reduced infarct volume in permanent and transient MCAO in rats using MRI up to 2 days. This study investigated the effect of chronic MB therapy on ischemic stroke volume along with behavioral score correlations 28 days after stroke. We administered MB at day 0, 2, 7, 14 and obtained stroke volume and functional behavioral measurements out to 28 days. We also used a new more aggressive treatment paradigm that involves doubling MB dose over permanent ischemia and after reperfusion. We hypothesized that this new MB treatment paradigm is safe, decreases final stroke volumes and functional sensorimotor deficit.

This abstract and the presentation materials are available to members only; a login is required.

Join Here